Purpose: To develop a simple pharmacodynamic (PD) assay for the evaluation of the bioequivalence of topically applied retinoid products. Methods: Daily applications of products containing tretinoin or adapalene were made to the forearms of human subjects for up to 21 days. Percutaneous absorption was enhanced through the use of polyethylene film occlusion (5 h). Pharmacologic activity was assessed through the daily measurement of three cutaneous responses intimately linked to retinoid-induced changes in epidermal differentiation: (1) erythema; (2) exfoliation (scaling/peeling), and (3) increased transepidermal water loss. Results: The PD model exhibited the sensitivity and specificity required to function as a bioequivalence surrogate. It was possible to differentiate between: (1) three concentrations of tretinoin in a commercial cream product line; (2) two concentrations of tretinoin in a commercial gel product line; (3) different vehicles (gel vs. cream) containing the same concentration of tretinoin, and (4) tretinoin and adapalene at the same concentration. The applicability of this model for bioequivalence testing was established by showing that it had sufficient power to determine that three test tretinoin cream products and two approved generic tretinoin gel products were equivalent to their corresponding reference products. Conclusions: A surrogate PD model to assess retinoid bioequivalence has been developed.

Keywords:
Adapalene, Bioequivalence, Pharmacodynamics, Retinoic acid, Retinoids, Transepidermal water loss, Tretinoin
1.
Food, Drug and Cosmetic Act and implementing regulations: 21 CFR §320 and 21 CFR §320.24.
2.
Guidance: Topical Dermatologic Corticosteroids: In vivo Bioequivalence. Rockville, Center for Drug Evaluation and Research, Food and Drug Administration, 1995. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070234.pdf.
3.
Elias PM, Williams ML: Retinoid effects on epidermal differentiation; in Saurat JH (ed): Retinoids: New Trends in Research and Therapy. Basel, Karger, 1984, pp 138–158.
4.
Plewig G, Braun-Falco O: Kinetics of epidermis and adnexa following vitamin A acid in the human. Acta Derm Vernereol Suppl (Stockh) 1975;74:87–98.
5.
Papa CM: The cutaneous safety of topical tretinoin. Acta Derm Vernereol Suppl (Stockh) 1975;74:128–132.
6.
Shalita AR: Topical acne therapy. Dermatol Clin 1983;1:399–403.
7.
Feldmann RJ, Maibach HI: Regional variation in percutaneous penetration of 14C-cortisol in man. J Invest Dermatol 1967;48:181–183.
8.
Lebwohl M, Herrmann LG: Impaired skin barrier function in dermatolgic disease and repair with moisturization. Cutis 2005;76(suppl 6):7–12.
9.
Pedace FJ, Stoughton R: Topical retinoic acid in acne vulgaris. Br J Dermatol 1971;84:465–469.
10.
Kligman AM, Plewig G: Treatment – General Statement; in Plewig G, Kligman A: Acne: Morphogenesis and Treatment. New York, Springer, 1975, chap 28, p 283.
11.
Kirsch J, Gibson JR, Darley CR, Barth J, Burke CA: Forearm site variation with the corticosteroid vasoconstrictor assay. Br J Dermatol 1982;106:495.
12.
van der Valk PGM, Maibach HI: Potential for irritation increases from the wrist to the cubital fossa. Br J Dermatol 1989;121:709–712.
13.
Rougier A, Lotte C, Corcuff P, Maibach HI: Relationship between skin permeability and corneocyte size according to anatomic site, age, and sex in man. J Soc Cosmet Chem 1988;39:15–26.
14.
Berner B, Liu P: Alcohols; in Smith EW, Maibach HI (eds): Percutaneous Penetration Enhancers. Boca Raton, CRC Press, 1995, pp 45–60.
15.
Boman AS: Irritants – organic solvents; in van der Valk PGM, Maibach HI (eds): The Irritant Contact Dermatitis Syndrome. Boca Raton, CRC Press, 1996, pp 95–104.
16.
Cunliffe WJ, Caputo R, Dreno B, et al: Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and US multicenter trials. J Am Acad Dermatol 1997;36:S126–S134.
17.
Dunlap FE, Mills OH, Tuley MR, Baker MD, Plott RT: Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998;139(suppl 52):17–22.
18.
Strauss JS: Sebaceous glands; in Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (eds): Dermatology in General Medicine, ed 4. New York, McGraw-Hill, 1993, p 718.
19.
Leyden JJ: Topical treatment of acne vulgaris: retinoids and cutaneous irritation. J Am Acad Dermatol 1998;38:S1–S4.
20.
Zaenglein AL, Thiboutot DM: Acne vulgaris; in Bolognia ML, Jorizzo JL, Rapini RP (eds): Dermatology, ed 2. Philadelphia, Mosby Elsevier, 2008, p 503.
21.
Tolman EL: Acne and acneiform dermatoses; in Moschella SL, Hurley HJ (eds): Dermatology, ed 3. Philadelphia, Saunders, 1992, p 1480.
22.
Franz TJ, Lehman PA, Raney SG: Use of excised human skin to assess the bioequivalence of topical products. Skin Pharmacol Physiol 2009;22:276–286.
23.
Pershing LK, Nelson JL, Corlett JL, Shrivastava SP, Hare DB, Shah VP: Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. J Am Acad Dermatol 2003;48:740–751.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.